新型流感衍生 HLA-B*18:01 限制性表位的特征描述

IF 4.6 2区 医学 Q2 IMMUNOLOGY Clinical & Translational Immunology Pub Date : 2024-05-10 DOI:10.1002/cti2.1509
Samuel Liwei Leong, Lawton Murdolo, Janesha C Maddumage, Marios Koutsakos, Katherine Kedzierska, Anthony W Purcell, Stephanie Gras, Emma J Grant
{"title":"新型流感衍生 HLA-B*18:01 限制性表位的特征描述","authors":"Samuel Liwei Leong,&nbsp;Lawton Murdolo,&nbsp;Janesha C Maddumage,&nbsp;Marios Koutsakos,&nbsp;Katherine Kedzierska,&nbsp;Anthony W Purcell,&nbsp;Stephanie Gras,&nbsp;Emma J Grant","doi":"10.1002/cti2.1509","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Seasonal influenza viruses cause roughly 650 000 deaths annually despite available vaccines. CD8<sup>+</sup> T cells typically recognise influenza-derived peptides from internal structural and non-structural influenza proteins and are an attractive avenue for future vaccine design as they could reduce the severity of disease following infection with diverse influenza strains. CD8<sup>+</sup> T cells recognise peptides presented by the highly polymorphic Human Leukocyte Antigens class I molecules (HLA-I). Each HLA-I variant has distinct peptide binding preferences, representing a significant obstacle for designing vaccines that elicit CD8<sup>+</sup> T cell responses across broad populations. Consequently, the rational design of a CD8<sup>+</sup> T cell-mediated vaccine would require the identification of highly immunogenic peptides restricted to a range of different HLA molecules.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Here, we assessed the immunogenicity of six recently published novel influenza-derived peptides identified by mass-spectrometry and predicted to bind to the prevalent HLA-B*18:01 molecule.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Using CD8<sup>+</sup> T cell activation assays and protein biochemistry, we showed that 3/6 of the novel peptides were immunogenic in several HLA-B*18:01<sup>+</sup> individuals and confirmed their HLA-B*18:01 restriction. We subsequently compared CD8<sup>+</sup> T cell responses towards the previously identified highly immunogenic HLA-B*18:01-restricted NP<sub>219</sub> peptide. Using X-ray crystallography, we solved the first crystal structures of HLA-B*18:01 presenting immunogenic influenza-derived peptides. Finally, we dissected the first TCR repertoires specific for HLA-B*18:01 restricted pathogen-derived peptides, identifying private and restricted repertoires against each of the four peptides.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Overall the characterisation of these novel immunogenic peptides provides additional HLA-B*18:01-restricted vaccine targets derived from the Matrix protein 1 and potentially the non-structural protein and the RNA polymerase catalytic subunit of influenza viruses.</p>\n </section>\n </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"13 5","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1509","citationCount":"0","resultStr":"{\"title\":\"Characterisation of novel influenza-derived HLA-B*18:01-restricted epitopes\",\"authors\":\"Samuel Liwei Leong,&nbsp;Lawton Murdolo,&nbsp;Janesha C Maddumage,&nbsp;Marios Koutsakos,&nbsp;Katherine Kedzierska,&nbsp;Anthony W Purcell,&nbsp;Stephanie Gras,&nbsp;Emma J Grant\",\"doi\":\"10.1002/cti2.1509\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objectives</h3>\\n \\n <p>Seasonal influenza viruses cause roughly 650 000 deaths annually despite available vaccines. CD8<sup>+</sup> T cells typically recognise influenza-derived peptides from internal structural and non-structural influenza proteins and are an attractive avenue for future vaccine design as they could reduce the severity of disease following infection with diverse influenza strains. CD8<sup>+</sup> T cells recognise peptides presented by the highly polymorphic Human Leukocyte Antigens class I molecules (HLA-I). Each HLA-I variant has distinct peptide binding preferences, representing a significant obstacle for designing vaccines that elicit CD8<sup>+</sup> T cell responses across broad populations. Consequently, the rational design of a CD8<sup>+</sup> T cell-mediated vaccine would require the identification of highly immunogenic peptides restricted to a range of different HLA molecules.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Here, we assessed the immunogenicity of six recently published novel influenza-derived peptides identified by mass-spectrometry and predicted to bind to the prevalent HLA-B*18:01 molecule.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Using CD8<sup>+</sup> T cell activation assays and protein biochemistry, we showed that 3/6 of the novel peptides were immunogenic in several HLA-B*18:01<sup>+</sup> individuals and confirmed their HLA-B*18:01 restriction. We subsequently compared CD8<sup>+</sup> T cell responses towards the previously identified highly immunogenic HLA-B*18:01-restricted NP<sub>219</sub> peptide. Using X-ray crystallography, we solved the first crystal structures of HLA-B*18:01 presenting immunogenic influenza-derived peptides. Finally, we dissected the first TCR repertoires specific for HLA-B*18:01 restricted pathogen-derived peptides, identifying private and restricted repertoires against each of the four peptides.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Overall the characterisation of these novel immunogenic peptides provides additional HLA-B*18:01-restricted vaccine targets derived from the Matrix protein 1 and potentially the non-structural protein and the RNA polymerase catalytic subunit of influenza viruses.</p>\\n </section>\\n </div>\",\"PeriodicalId\":152,\"journal\":{\"name\":\"Clinical & Translational Immunology\",\"volume\":\"13 5\",\"pages\":\"\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-05-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1509\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Translational Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cti2.1509\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cti2.1509","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

尽管有疫苗可用,但季节性流感病毒每年仍会导致大约 65 万人死亡。CD8+ T 细胞通常能识别来自内部结构和非结构性流感蛋白的流感衍生肽,是未来疫苗设计的一个有吸引力的途径,因为它们能降低感染不同流感病毒株后的疾病严重程度。CD8+ T 细胞能识别由高度多态的人类白细胞抗原 I 类分子(HLA-I)呈现的肽。每种 HLA-I 变体都有不同的肽结合偏好,这对设计能在广泛人群中引起 CD8+ T 细胞反应的疫苗构成了重大障碍。因此,要合理设计 CD8+ T 细胞介导的疫苗,就必须鉴定出限制于一系列不同 HLA 分子的高免疫原性肽。 方法 在此,我们评估了最近发表的六种新型流感衍生肽的免疫原性,这些肽是通过质谱分析鉴定的,并预测能与流行的 HLA-B*18:01 分子结合。 结果 我们使用 CD8+ T 细胞活化试验和蛋白质生物化学方法表明,3/6 种新型多肽在几个 HLA-B*18:01+ 的个体中具有免疫原性,并证实了它们的 HLA-B*18:01 限制。随后,我们比较了 CD8+ T 细胞对之前发现的高免疫原性 HLA-B*18:01 限制性 NP219 肽的反应。通过 X 射线晶体学,我们首次解析了 HLA-B*18:01 呈现免疫原性流感衍生肽的晶体结构。最后,我们剖析了首个针对 HLA-B*18:01 限制性病原体衍生肽的特异性 TCR 反应谱,确定了针对四种肽中每一种肽的私有和限制性反应谱。 结论 总的来说,这些新型免疫原性多肽的特征描述提供了更多的 HLA-B*18:01 限制性疫苗靶标,这些靶标来自基质蛋白 1,也可能来自流感病毒的非结构蛋白和 RNA 聚合酶催化亚基。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Characterisation of novel influenza-derived HLA-B*18:01-restricted epitopes

Objectives

Seasonal influenza viruses cause roughly 650 000 deaths annually despite available vaccines. CD8+ T cells typically recognise influenza-derived peptides from internal structural and non-structural influenza proteins and are an attractive avenue for future vaccine design as they could reduce the severity of disease following infection with diverse influenza strains. CD8+ T cells recognise peptides presented by the highly polymorphic Human Leukocyte Antigens class I molecules (HLA-I). Each HLA-I variant has distinct peptide binding preferences, representing a significant obstacle for designing vaccines that elicit CD8+ T cell responses across broad populations. Consequently, the rational design of a CD8+ T cell-mediated vaccine would require the identification of highly immunogenic peptides restricted to a range of different HLA molecules.

Methods

Here, we assessed the immunogenicity of six recently published novel influenza-derived peptides identified by mass-spectrometry and predicted to bind to the prevalent HLA-B*18:01 molecule.

Results

Using CD8+ T cell activation assays and protein biochemistry, we showed that 3/6 of the novel peptides were immunogenic in several HLA-B*18:01+ individuals and confirmed their HLA-B*18:01 restriction. We subsequently compared CD8+ T cell responses towards the previously identified highly immunogenic HLA-B*18:01-restricted NP219 peptide. Using X-ray crystallography, we solved the first crystal structures of HLA-B*18:01 presenting immunogenic influenza-derived peptides. Finally, we dissected the first TCR repertoires specific for HLA-B*18:01 restricted pathogen-derived peptides, identifying private and restricted repertoires against each of the four peptides.

Conclusion

Overall the characterisation of these novel immunogenic peptides provides additional HLA-B*18:01-restricted vaccine targets derived from the Matrix protein 1 and potentially the non-structural protein and the RNA polymerase catalytic subunit of influenza viruses.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical & Translational Immunology
Clinical & Translational Immunology Medicine-Immunology and Allergy
CiteScore
12.00
自引率
1.70%
发文量
77
审稿时长
13 weeks
期刊介绍: Clinical & Translational Immunology is an open access, fully peer-reviewed journal devoted to publishing cutting-edge advances in biomedical research for scientists and physicians. The Journal covers fields including cancer biology, cardiovascular research, gene therapy, immunology, vaccine development and disease pathogenesis and therapy at the earliest phases of investigation.
期刊最新文献
Autologous Epstein-Barr virus-specific adoptive T-cell therapy in a patient with lupus nephritis. The contribution of the CRP/CD64 axis to renal cancer progression by inducing protumor activation of tumor-associated macrophages. Natural killer cell antibody-dependent cellular cytotoxicity to Plasmodium falciparum is impacted by cellular phenotypes, erythrocyte polymorphisms, parasite diversity and intensity of transmission Naturally acquired adaptive immunity to Streptococcus pneumoniae is impaired in rheumatoid arthritis patients Inhibitory effect of hydroxychloroquine on glucocorticoid-induced osteoporosis in lupus therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1